ERBB2 and triple-negative breast carcinoma: Of those with data, 38 of 269 had subtype A, 63 of 307 had subtype B, 14 of 79 had luminal HER2-positive disease, 3 of 31 had non-luminal HER2-positive disease, and 12 of 58 had triple-negative breast cancer (TNBC).